SCHEMBL11419626

SCHEMBL11419626

CN(Cc1cccc(-c2ccc(C(=O)NCC3CCN(Cc4ccccc4)CC3)cc2)c1)C(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 5/20 0.51
▸ HDAC4 P56524 5/20 0.51
▸ HDAC1 Q13547 5/20 0.51
▸ HDAC7 Q8WUI4 5/20 0.51
▸ HDAC2 Q92769 5/20 0.51
▸ HDAC10 Q969S8 5/20 0.51
▸ HDAC11 Q96DB2 5/20 0.51
▸ HDAC8 Q9BY41 5/20 0.51
▸ HDAC6 Q9UBN7 5/20 0.51
▸ HDAC9 Q9UKV0 5/20 0.51
▸ HDAC5 Q9UQL6 5/20 0.51
▸ CHRM4 P08173 7/20 0.50
▸ AOC3 Q16853 2/20 0.47
▸ ACACB O00763 2/20 0.47
▸ ACACA Q13085 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ CHRM2 P08172 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ FAAH O00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11423162 0.87 AOC3 (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11421859 0.87 DRD2 (0.60) CHRM4
SCHEMBL11357938 0.87 CHRM4 (0.49) CHRM4AOC3ACHE
SCHEMBL11420809 0.87 AOC3 (0.51) AOC3ACACBACACA
SCHEMBL11422630 0.85 HTR5A (0.52) AOC3BCHEACHE
SCHEMBL11366530 0.83 KMT2A (0.52) AOC3KDM4E
SCHEMBL11424224 0.81 USP30 (0.49) AOC3BCHEACHE
SCHEMBL11422215 0.80 AOC3 (0.49) AOC3
SCHEMBL11360718 0.80 AOC3 (0.54) AOC3
SCHEMBL10319556 0.80 AOC3 (0.65) AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 — — EP disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 — — US disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 — — US disclosed
WO-2011034078-A1 GLYCINE COMPOUND アステラス製薬株式会社 (JP) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184520-A1 GLYCINE COMPOUND SLC5A1, AQP1, VAPB HDAC3 4730/4885HDAC4 4777/4885HDAC1 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback